Skip to content

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Safety, PK, & Efficacy of a Single Oral Dose of XPF-001 in the Treatment of Pain Related to Third Molar/Wisdom Tooth Extraction.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00954356
Enrollment
61
Registered
2009-08-07
Start date
2009-09-30
Completion date
2009-12-31
Last updated
2012-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Pain

Keywords

Pain following 3rd molar/wisdom tooth extraction

Brief summary

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Interventions

Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)

DRUGplacebo

Single oral administration of 5 x 100 mg Placebo capsules.

Sponsors

Xenon Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Males (aged 18-60) and females of non-childbearing potential (aged 18-60; * BMI between 19.5 to 32.0 kg/m2; * Outpatient, scheduled to undergo surgical extraction of 2 or more impacted 3rd molars (with at least 1 partial bony mandibular extraction); * use of only the following preoperative medications 2% lidocaine with epinephrine and nitrous oxide; * Able to complete the requested information on analgesic questionnaires and able to comply with study procedures and restrictions; * Able to read, comprehend and sign the consent form; * Deemed medically healthy to participate in the study, with normal or clinically insignificant medical history, physical examination, lab tests and ECG results; * No contraindications to the study drug, it excipients or any of the study medications including rescue medications.

Exclusion criteria

* Presence of a clinically significant medical condition; * Positive test for HIV, Hepatitis B or Hepatitis C; * Use of any prescription or over the counter medication or supplement in the 48 hours before dose of study drug until discharge; * Acute local infection at the time of dental surgery; * Females who are pregnant, lactating or of child-bearing potential, or who provide a positive pregnancy test result at screening or check-in; * Males not undertaking adequate measures to prevent their partner becoming pregnant throughout the study; * Clinically significant laboratory values; * Clinically significant abnormal ECG; * History or presence of alcoholism, or alcohol or substance abuse (within previous 2 years), or routine consumption of 3 or more alcoholic drinks per day; * A positive urine drug test; * Routine use of analgesics 5 or more times per week; * Presence or history (within 2 years of enrolment) of bleeding disorder(s) or peptic ulcer disease; * History of allergic reaction to any drug, including penicillin; * Ingestion of caffeine containing foods or drinks in the 24 hours before dose of study drug; * Consumption of alcohol in the 48 hours before dose of study drug, or a positive alcohol breath test at check-in; * Consumption of grapefruit or grapefruit containing products in the 7 days before dose of study drug; * Use of tobacco or nicotine substitutes within 1 month of dose of study drug, or inability to refrain from use of nicotine between check-in and follow up; * Treatment for depression in the 6 months prior to enrolment; * Use of another investigational drug in the 60 days before enrolment; * Donation or loss of 50-500 mL of blood in the 30 days prior to enrolment, or more than 500 mL of blood in the 56 days before enrolment; * Previously entered into this study; * Study site or Sponsor employees or relatives of employees directly involved in the study; * Any other condition that (in the opinion of the Investigator or sponsor) makes the subject unsuitable for the study.

Design outcomes

Primary

MeasureTime frameDescription
Total Pain Relief at 6 Hours Post Dose (TOTPAR 6)6 hours post doseThe primary efficacy variable was total pain relief at the 6-hour observation (TOTPAR 6); TOTPAR 6 is an area calculation incorporating time and relief scores over the 6 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 6 score = 0, maximum possible score = 24

Secondary

MeasureTime frameDescription
Total Pain Relief (TOTPAR) at 8 Hours Post Dose8 hoursA secondary efficacy variable was total pain relief at the 8-hour observation (TOTPAR 8); TOTPAR 8 is an area calculation incorporating time and relief scores over the 8 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 8 score = 0, maximum possible score = 32
Total Pain Relief (TOTPAR) at 12 Hours Post Dose12 hoursA secondary efficacy variable was total pain relief at the 12-hour observation (TOTPAR 12); TOTPAR 12 is an area calculation incorporating time and relief scores over the 12 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 12 score = 0, maximum possible score = 48.
Summed Pain Intensity Difference (SPID) at 4 Hours Post DoseBaseline to 4 hours post dosePain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID4 is an area calculation encompassing time and the PID scores over the 4 hours following dosing. The minimum possible SPID4 value = -40, the maximum possible = 40. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.
Summed Pain Intensity Difference (SPID) at 6 Hours Post DoseBaseline to 6 hours post dosePain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID6 is an area calculation encompassing time and the PID scores over the 6 hours following dosing. The minimum possible SPID6 value = -60, the maximum possible = 60. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.
Summed Pain Intensity Difference (SPID) at 8 Hours Post DoseBaseline to 8 hours post dosePain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID8 is an area calculation encompassing time and the PID scores over the 8 hours following dosing. The minimum possible SPID8 value = -80, the maximum possible = 80. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.
Total Pain Relief (TOTPAR) at 4 Hours Post Dose4 hoursA secondary efficacy variable was total pain relief at the 4-hour observation (TOTPAR 4); TOTPAR 4 is an area calculation incorporating time and relief scores over the 4 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 4 score = 0, maximum possible score = 16).
Time to First Perceptible Relief24 hoursOnset of analgesia was measured using 2 stopwatches. Both stopwatches were started at the time of dose administration. Stopwatch 1 was pressed by the subject when any pain relief was first perceived (Time to First Perceptible Relief) and stopwatch 2 was pressed by the subject when pain relief became meaningful (Time to Meaningful Relief).
Time to Meaningful Relief24 hoursOnset of analgesia was measured using 2 stopwatches. Both stopwatches were started at the time of dose administration. Stopwatch 1 was pressed by the subject when any pain relief was first perceived (Time to First Perceptible Relief) and stopwatch 2 was pressed by the subject when pain relief became meaningful (Time to Meaningful Relief). 'Meaningful Relief' was defined as when the relief became 'meaningful' to each individual subject, and was not necessarily a complete absence of pain. 'Meaningful Relief' could not occur before 'First Perceptible Relief'.
Time to Rescue Medication24 hoursThe time of administration of rescue medication (if any) was recorded for each subject and the duration since dosing was calculated.
Treatment Emergent Adverse Events48 hoursAdverse Events were recorded at the time of occurence. Clinically significant findings (if any) in ECG and vital signs assessments and laboratory samples were recorded as adverse events. Treatment Emergent Adverse Events (TEAEs) are those which either started or worsened following administration of study drug (XPF-001 or placebo).
Summed Pain Intensity Difference (SPID) at 12 Hours Post DoseBaseline to 12 hours post dosePain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID12 is an area calculation encompassing time and the PID scores over the 12 hours following dosing. The minimum possible SPID12 value = -120, the maximum possible = 120. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.

Countries

United States

Participant flow

Recruitment details

All 61 subjects were recruited at a single center between September 29th and November 16th 2009.

Participants by arm

ArmCount
XPF-001
500 mg XEN402 (5x 100 mg capsules) administered as a single dose
41
Placebo
5 x matching placebo capsules (administered as a single dose)
20
Total61

Baseline characteristics

CharacteristicPlaceboXPF-001Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants41 Participants61 Participants
Age Continuous20.9 years
STANDARD_DEVIATION 3.01
20.2 years
STANDARD_DEVIATION 2.94
20.4 years
STANDARD_DEVIATION 2.96
Region of Enrollment
United States
20 participants41 participants61 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
20 Participants41 Participants61 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
16 / 414 / 20
serious
Total, serious adverse events
0 / 410 / 20

Outcome results

Primary

Total Pain Relief at 6 Hours Post Dose (TOTPAR 6)

The primary efficacy variable was total pain relief at the 6-hour observation (TOTPAR 6); TOTPAR 6 is an area calculation incorporating time and relief scores over the 6 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 6 score = 0, maximum possible score = 24

Time frame: 6 hours post dose

Population: Published data from an impacted wisdom tooth removal was used to determine a 60 subject study with 2:1 randomisation and a one-sided significance level of 0.10 would have a power of 84.1%. LOCF was used for imputed values and all subjects were included in both the IIT and PP populations for analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboTotal Pain Relief at 6 Hours Post Dose (TOTPAR 6)2.45 units on a scale
XPF-001Total Pain Relief at 6 Hours Post Dose (TOTPAR 6)4.37 units on a scale
Secondary

Summed Pain Intensity Difference (SPID) at 12 Hours Post Dose

Pain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID12 is an area calculation encompassing time and the PID scores over the 12 hours following dosing. The minimum possible SPID12 value = -120, the maximum possible = 120. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.

Time frame: Baseline to 12 hours post dose

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboSummed Pain Intensity Difference (SPID) at 12 Hours Post Dose-1.10 units on a scale
XPF-001Summed Pain Intensity Difference (SPID) at 12 Hours Post Dose5.68 units on a scale
Secondary

Summed Pain Intensity Difference (SPID) at 4 Hours Post Dose

Pain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID4 is an area calculation encompassing time and the PID scores over the 4 hours following dosing. The minimum possible SPID4 value = -40, the maximum possible = 40. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.

Time frame: Baseline to 4 hours post dose

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboSummed Pain Intensity Difference (SPID) at 4 Hours Post Dose-0.577 units on a scale
XPF-001Summed Pain Intensity Difference (SPID) at 4 Hours Post Dose0.364 units on a scale
Secondary

Summed Pain Intensity Difference (SPID) at 6 Hours Post Dose

Pain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID6 is an area calculation encompassing time and the PID scores over the 6 hours following dosing. The minimum possible SPID6 value = -60, the maximum possible = 60. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.

Time frame: Baseline to 6 hours post dose

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboSummed Pain Intensity Difference (SPID) at 6 Hours Post Dose-0.811 units on a scale
XPF-001Summed Pain Intensity Difference (SPID) at 6 Hours Post Dose1.48 units on a scale
Secondary

Summed Pain Intensity Difference (SPID) at 8 Hours Post Dose

Pain intensity was scored on an 11-point scale (PINRS), (0=no pain - 10=pain as bad as you can imagine). Scores were measured at baseline (after surgery but before dosing) and at multiple timepoints after dosing. At each timepoint, pain intensity difference (PID) was calculated (ie, baseline score minus timepoint score). SPID8 is an area calculation encompassing time and the PID scores over the 8 hours following dosing. The minimum possible SPID8 value = -80, the maximum possible = 80. A positive SPID LS Means score implies reduced pain intensity over the corresponding time period.

Time frame: Baseline to 8 hours post dose

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboSummed Pain Intensity Difference (SPID) at 8 Hours Post Dose-0.958 units on a scale
XPF-001Summed Pain Intensity Difference (SPID) at 8 Hours Post Dose2.77 units on a scale
Secondary

Time to First Perceptible Relief

Onset of analgesia was measured using 2 stopwatches. Both stopwatches were started at the time of dose administration. Stopwatch 1 was pressed by the subject when any pain relief was first perceived (Time to First Perceptible Relief) and stopwatch 2 was pressed by the subject when pain relief became meaningful (Time to Meaningful Relief).

Time frame: 24 hours

ArmMeasureValue (MEDIAN)
PlaceboTime to First Perceptible ReliefNA Minutes
XPF-001Time to First Perceptible ReliefNA Minutes
Secondary

Time to Meaningful Relief

Onset of analgesia was measured using 2 stopwatches. Both stopwatches were started at the time of dose administration. Stopwatch 1 was pressed by the subject when any pain relief was first perceived (Time to First Perceptible Relief) and stopwatch 2 was pressed by the subject when pain relief became meaningful (Time to Meaningful Relief). 'Meaningful Relief' was defined as when the relief became 'meaningful' to each individual subject, and was not necessarily a complete absence of pain. 'Meaningful Relief' could not occur before 'First Perceptible Relief'.

Time frame: 24 hours

ArmMeasureValue (MEDIAN)
PlaceboTime to Meaningful ReliefNA Minutes
XPF-001Time to Meaningful ReliefNA Minutes
Secondary

Time to Rescue Medication

The time of administration of rescue medication (if any) was recorded for each subject and the duration since dosing was calculated.

Time frame: 24 hours

ArmMeasureValue (MEDIAN)
PlaceboTime to Rescue Medication93 Minutes
XPF-001Time to Rescue Medication133 Minutes
Secondary

Total Pain Relief (TOTPAR) at 12 Hours Post Dose

A secondary efficacy variable was total pain relief at the 12-hour observation (TOTPAR 12); TOTPAR 12 is an area calculation incorporating time and relief scores over the 12 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 12 score = 0, maximum possible score = 48.

Time frame: 12 hours

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboTotal Pain Relief (TOTPAR) at 12 Hours Post Dose5.42 units on a scale
XPF-001Total Pain Relief (TOTPAR) at 12 Hours Post Dose10.7 units on a scale
Secondary

Total Pain Relief (TOTPAR) at 4 Hours Post Dose

A secondary efficacy variable was total pain relief at the 4-hour observation (TOTPAR 4); TOTPAR 4 is an area calculation incorporating time and relief scores over the 4 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 4 score = 0, maximum possible score = 16).

Time frame: 4 hours

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboTotal Pain Relief (TOTPAR) at 4 Hours Post Dose1.51 units on a scale
XPF-001Total Pain Relief (TOTPAR) at 4 Hours Post Dose2.44 units on a scale
Secondary

Total Pain Relief (TOTPAR) at 8 Hours Post Dose

A secondary efficacy variable was total pain relief at the 8-hour observation (TOTPAR 8); TOTPAR 8 is an area calculation incorporating time and relief scores over the 8 hours following dosing and was calculated using Simpson's trapezoidal rule. The higher the LS Means scores, the more pain relief was obtained. Relief (REL) scores were measured at multiple timepoints after dosing, using a 5 point categorical pain relief rating scale. (None = 0, A Little Relief = 1, Some = 2, A Lot = 3, Complete Relief = 4). The minimum possible TOTPAR 8 score = 0, maximum possible score = 32

Time frame: 8 hours

ArmMeasureValue (LEAST_SQUARES_MEAN)
PlaceboTotal Pain Relief (TOTPAR) at 8 Hours Post Dose3.43 units on a scale
XPF-001Total Pain Relief (TOTPAR) at 8 Hours Post Dose6.41 units on a scale
Secondary

Treatment Emergent Adverse Events

Adverse Events were recorded at the time of occurence. Clinically significant findings (if any) in ECG and vital signs assessments and laboratory samples were recorded as adverse events. Treatment Emergent Adverse Events (TEAEs) are those which either started or worsened following administration of study drug (XPF-001 or placebo).

Time frame: 48 hours

ArmMeasureValue (NUMBER)
PlaceboTreatment Emergent Adverse Events7 Events
XPF-001Treatment Emergent Adverse Events35 Events

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026